S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation

NCT07722312 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Acute Leukemia
Relapsed or Refractory Acute Myeloid Leukemia

Interventions

DRUG: S243249 600mg
DRUG: S243249 400mg
DRUG: S243249 450mg
DRUG: S243249 300mg

Sponsor

Servier